Table 3.
Adverse events of combination therapy reported in glioma trials.
| Dabrafenib + Trametinib (22) | Dabrafenib + Trametinib (29) | ||||
|---|---|---|---|---|---|
| Toxicity | Any (%) | Grade >=3 (%) | Toxicity | Grades 1–2 (%) | Grade >=3 (%) |
| Any | 100 | 47 | Any | 92 | 53 |
| Pyrexia | 68 | 8 | Fatigue | 41 | 9 |
| Headache | 47 | 1 | Headache | 38 | 5 |
| Vomiting | 34 | 1 | Nausea | 33 | 2 |
| Fatigue | 32 | 0 | Pyrexia | 31 | 2 |
| Diarrhea | 29 | 0 | Rash | 29 | 0 |
| Dry skin | 26 | 0 | Vomiting | 26 | 2 |
| Nausea | 25 | 0 | Anemia | 22 | 0 |
| Anemia | 15 | 0 | Constipation | 21 | 0 |
| ALT increased | 14 | 5 | Arthralgia | 21 | 2 |
| Neutropenia | 14 | 10 | AST/ALT increased | 17 | 3 |
| Neutrophil count decreased | 14 | 5 | Myalgia | 14 | 2 |
| Constipation | 12 | 0 | Diarrhea | 14 | 2 |
| WBC count decreased | 11 | 0 | Neutropenia | 10 | 5 |
| Platelet count decreased | 5 | 0 | Ejection fraction decreased | 10 | 2 |